WO2012102560A3 - Nouveau dérivé de 4-0-méthylhonokiol et composition contenant ce dérivé en tant que principe actif pour traiter des maladies inflammatoires - Google Patents

Nouveau dérivé de 4-0-méthylhonokiol et composition contenant ce dérivé en tant que principe actif pour traiter des maladies inflammatoires Download PDF

Info

Publication number
WO2012102560A3
WO2012102560A3 PCT/KR2012/000616 KR2012000616W WO2012102560A3 WO 2012102560 A3 WO2012102560 A3 WO 2012102560A3 KR 2012000616 W KR2012000616 W KR 2012000616W WO 2012102560 A3 WO2012102560 A3 WO 2012102560A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory diseases
novel
treatment
composition containing
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/000616
Other languages
English (en)
Korean (ko)
Other versions
WO2012102560A2 (fr
Inventor
한상배
정재경
곽영신
서승용
이기호
송석길
홍진태
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyundai Bioland Co Ltd
Original Assignee
Bioland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioland Ltd filed Critical Bioland Ltd
Publication of WO2012102560A2 publication Critical patent/WO2012102560A2/fr
Publication of WO2012102560A3 publication Critical patent/WO2012102560A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/205—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/205—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
    • C07C43/2055—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring containing more than one ether bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/28—Ethers with hydroxy compounds containing oxirane rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un nouveau dérivé de méthylhonokiol et une composition contenant ce dérivé en tant que principe actif pour traiter, prévenir ou atténuer des maladies inflammatoires. Ce dérivé de méthylhonokiol permet d'inhiber les activités de la COX-2(Cyclooxigénase-2), ce qui permet d'assurer des activités anti-inflammatoires. Ainsi, ce dérivé de méthylhonokiol peut être développé en tant qu'agent thérapeutique pour des maladies anti-inflammatoires variées et en tant que principe actif d'aliments fonctionnels.
PCT/KR2012/000616 2011-01-26 2012-01-26 Nouveau dérivé de 4-0-méthylhonokiol et composition contenant ce dérivé en tant que principe actif pour traiter des maladies inflammatoires Ceased WO2012102560A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110007844A KR101386068B1 (ko) 2011-01-26 2011-01-26 신규한 4-ｏ-메틸호노키올 유도체 및 이를 유효성분으로 포함하는 염증질환 치료용 조성물
KR10-2011-0007844 2011-01-26

Publications (2)

Publication Number Publication Date
WO2012102560A2 WO2012102560A2 (fr) 2012-08-02
WO2012102560A3 true WO2012102560A3 (fr) 2012-10-18

Family

ID=46581294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/000616 Ceased WO2012102560A2 (fr) 2011-01-26 2012-01-26 Nouveau dérivé de 4-0-méthylhonokiol et composition contenant ce dérivé en tant que principe actif pour traiter des maladies inflammatoires

Country Status (2)

Country Link
KR (1) KR101386068B1 (fr)
WO (1) WO2012102560A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486419B2 (en) 2013-04-17 2016-11-08 Ariel-University Research And Development Company CB2 receptor ligands for the treatment of psychiatric disorders
KR101941221B1 (ko) * 2017-12-14 2019-01-22 (주)솔빛피앤에프 노근 추출물을 유효성분으로 하는 황반변성 예방, 개선 또는 치료용 조성물
CN113999191B (zh) * 2021-11-25 2023-07-18 大连理工大学 一种含活性酯侧基新型生物基环氧树脂及其制备方法
WO2023182871A1 (fr) * 2022-03-25 2023-09-28 바스테라 주식회사 Dérivé de 3-phénylisoxazole et composition pharmaceutique pour prévenir ou traiter une maladie oculaire le contenant en tant que principe actif
WO2025116596A1 (fr) * 2023-11-29 2025-06-05 가천대학교 산학협력단 Nouveau composé et composition pour la prévention ou le traitement de maladies oculaires le contenant
CN118666734A (zh) * 2024-05-27 2024-09-20 上海植瑞新成医药科技有限公司 一种和厚朴酚衍生物及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080105526A (ko) * 2007-05-31 2008-12-04 주식회사 바이오랜드 후박 추출물 또는 이로부터 분리된 ４-ｏ-메틸호노키올을유효성분으로 함유하는 항염, 항알러지 및 주름 개선용조성물
KR100919625B1 (ko) * 2007-08-31 2009-09-30 서울대학교산학협력단 후박 추출물 또는 추출정제물을 포함하는 지방간 질환 예방및 치료용 조성물, 및 추출정제물의 제조방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080105526A (ko) * 2007-05-31 2008-12-04 주식회사 바이오랜드 후박 추출물 또는 이로부터 분리된 ４-ｏ-메틸호노키올을유효성분으로 함유하는 항염, 항알러지 및 주름 개선용조성물
KR100919625B1 (ko) * 2007-08-31 2009-09-30 서울대학교산학협력단 후박 추출물 또는 추출정제물을 포함하는 지방간 질환 예방및 치료용 조성물, 및 추출정제물의 제조방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OH, JU HOON ET AL.: "Anti-inflammatory effect of 4-O-methylhonokiol, a novel compound isolated from Magnolia officinalis through inhibition ofNF-kB", CHEMICO-BIOLOGICAL INTERACTIONS, vol. 180, 2009, pages 506 - 514, XP026194297, DOI: doi:10.1016/j.cbi.2009.03.014 *
SOLANKI, P. R ET AL.: "Synthesis and Physical Properties of Some Substitued Pyrazole and Isoxazole Complexes with Co (II), Ni (III) and Cu (II) Metal Ions", J. IND. COUNCIL CHEM., vol. 24, 2007, pages 43 - 45 *

Also Published As

Publication number Publication date
KR20120086538A (ko) 2012-08-03
WO2012102560A2 (fr) 2012-08-02
KR101386068B1 (ko) 2014-04-21

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
ZA201606320B (en) Human plasma kallikrein inhibitors
WO2015077503A8 (fr) Composés inhibiteurs de l'autotaxine
WO2012064973A3 (fr) Composés hétérocycliques et utilisations de ceux-ci
HK1199725A1 (en) Heterocyclic compounds and uses thereof
HK1198443A1 (en) Heterocyclic compounds and uses thereof
HK1207069A1 (en) Heterocyclic compounds and uses thereof
WO2012047587A3 (fr) Inhibiteurs de mdm2 pour le traitement d'affections oculaires
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
HK1206726A1 (en) Imidazotriazinone compounds
GEP20207172B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
WO2012125544A3 (fr) Inhibiteurs de la nécroptose et leurs méthodes d'utilisation
WO2011113060A3 (fr) Composés antiviraux et procédés d'utilisation de ceux-ci
WO2013134047A3 (fr) Dérivés d'aminoquinoléine et leurs utilisations
WO2011090270A3 (fr) Composition contenant de l'osmotine pour prévenir et traiter des troubles neurologiques
WO2015015378A3 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
WO2015066302A3 (fr) Compositions, méthodes d'utilisation et méthodes de traitement
WO2011150201A3 (fr) Composés azolylamide et leurs procédés d'utilisation
BR112013015877A2 (pt) composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
WO2012104240A3 (fr) Utilisation cosmétique
PH12017500563A1 (en) Stabilized adrenomedullin derivatives and use thereof
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
WO2011149301A3 (fr) Composition comprenant l'extrait de physalis alkekengi var. francheti hort en tant que principe actif pour la prévention et le traitement de maladies inflammatoires
WO2014064652A3 (fr) Composition pharmaceutique stable d'interféron pégylé alpha-2b
HK1198296A1 (en) N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12739382

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12739382

Country of ref document: EP

Kind code of ref document: A2